Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion submitted an application for a Phase 3 Clinical Trial Plan (Part 1) to the European Medicines Agency (EMA) for CT-P44, a biosimilar candidate referencing Darzalex, targeting patients with refractory or relapsed multiple myeloma.
📊 Key Disclosure Content & Financial Highlights
- Overview
- Company: Celltrion, Inc. (Stock Code: 068270)
- Disclosure Type: Major Matters Report Related to Investment Decisions
- Subject: Submission of Application for Phase 3 Clinical Trial Plan (Part 1) for CT-P44 (Darzalex Biosimilar) to European EMA
- Regulatory Authority: European Medicines Agency (EMA)
- Application Date (Local Time): 2024-11-27
- Confirmation Date: 2024-11-27 (Date CTA Part 1 submission to EMA was confirmed)
- Clinical Trial Details
- Study Title: A Double-Blind, Randomized, Active-Controlled, Parallel-Group, Phase 3 Clinical Trial to Compare the Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination with Lenalidomide and Dexamethasone in Subjects with Refractory or Relapsed Multiple Myeloma
- Phase: Global Phase 3
- Target Indication: Refractory or Relapsed Multiple Myeloma
- Registration Number: EU CT number 2024-518588-36-00
- Patient Count: 486 subjects
- Duration: 2 years
- Purpose: To demonstrate biosimilarity by comparing efficacy and safety between CT-P44 and Darzalex
- Regulatory Process & Investment Risks
- This submission covers Part 1 (assessment of trial design and methodology) under the revised EU Clinical Trials Regulation. Approval of both Part 1 and Part 2 is required to initiate the trial.
- Celltrion plans to demonstrate biosimilarity through efficacy and safety results compared to the reference drug Darzalex in this Phase 3 trial.
- Statistically, the probability of a clinical-stage drug candidate receiving final authorization is approximately 10%. Commercialization plans may be altered or abandoned based on trial outcomes.
- Content of this disclosure will be utilized in upcoming press releases and IR materials.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Monitoring European EMA Approval of Phase 3 Clinical Trial Plan (Part 1 & Part 2)
This disclosure serves as official notification that Celltrion submitted an application for a Phase 3 Clinical Trial Plan (Part 1) for CT-P44 to the European EMA. Tracking whether EMA approval for Part 1 is secured and subsequent Part 2 submission/approval is completed is important for monitoring trial initiation. Relevant updates can be confirmed through subsequent disclosures or official IR materials.
📢 Disclaimer & Source Notice
Source: This content was structured and generated based on official disclosure data from the Financial Supervisory Service’s DART system.
Investment Risk Warning: This material is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
